Media coverage about Sientra (NASDAQ:SIEN) has been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sientra earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news coverage about the medical instruments supplier an impact score of 45.3762957663769 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Shares of Sientra (NASDAQ SIEN) traded down $0.87 during mid-day trading on Monday, reaching $11.65. 303,600 shares of the company’s stock traded hands, compared to its average volume of 184,211. The firm has a market cap of $226.03, a price-to-earnings ratio of -4.09 and a beta of -1.47. Sientra has a 52 week low of $7.20 and a 52 week high of $16.68. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.92 and a current ratio of 2.87.
Sientra (NASDAQ:SIEN) last released its earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.74) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.06). The company had revenue of $9.80 million for the quarter, compared to analyst estimates of $10.54 million. Sientra had a negative net margin of 169.77% and a negative return on equity of 68.82%. The firm’s quarterly revenue was up 50.8% on a year-over-year basis. During the same period in the previous year, the business posted ($0.55) EPS. equities research analysts predict that Sientra will post -3.23 earnings per share for the current fiscal year.
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.